Table 2 Clinicopathological characteristics in association with ROS1, ALK, PD-1, and PD-L1 proteins expression
| Â | Â | ROS1 | ALK | PD-1 | PD-L1 | ||||
|---|---|---|---|---|---|---|---|---|---|
No | -ve | +ve | -ve | +ve | -ve | +ve | -ve | +ve | |
Age | |||||||||
 < 55 | 32 | 27 (84.4) | 5 (15.6) | 14 (43.75) | 18 (56.25) | 4 (12.5) | 28 (87.5) | 4 (12.5) | 28 (87.5) |
 ≥ 55 | 38 | 30 (78.9) | 8 (21.1) | 18 (47.4) | 20 (52.6) | 7 (18.4) | 31 (81.6) | 5 (13.2) | 33 (86.8) |
 ap-value |  | 0.76 | 0.81 | 0.53 | 1.00 | ||||
Gender | |||||||||
 Female | 19 | 16 (84.2) | 3 (15.8) | 9 (47.4) | 10 (52.6) | 5 (26.3) | 14 (73.7) | 4 (21.1) | 15 (78.9) |
 Male | 51 | 41 (80.4) | 10 (19.6) | 23 (45.1) | 28 (54.9) | 6 (11.8) | 45 (88.2) | 5 (9.8) | 46 (90.2) |
 ap-value |  | 1.00 | 1.00 | 0.15 | 0.24 | ||||
Smoking status | |||||||||
 Never-smoker | 27 | 22 (81.5) | 5 (18.5) | 13 (48.1) | 14 (51.9) | 5 (18.5) | 22 (81.5) | 3 (11.1) | 24 (88.9) |
 Current/ex-smoker | 41 | 35 (81.4) | 8 (18.6) | 19 (44.2) | 24 (55.8) | 6 (13.95) | 37 (86.05) | 6 (13.95) | 37 (86.05) |
 ap-value |  | 1.00 | 0.81 | 0.74 | 1.00 | ||||
Grade | |||||||||
 1–2 | 51 | 41 (80.4) | 10 (19.6) | 24 (47.1) | 27 (52.9) | 7 (13.7) | 44 (86.3) | 8 (15.7) | 43 (84.3) |
 3 | 19 | 16 (84.2) | 3 (15.8) | 8 (42.1) | 11 (57.9) | 4 (21.1) | 15 (78.9) | 1 (5.3) | 18 (94.7) |
 ap-value |  | 1.00 | 0.79 | 0.47 | 0.43 | ||||
Stage | |||||||||
 I | 12 | 8 (66.7) | 4 (33.3) | 10 (83.3) | 2 (16.7) | 3 (25.0) | 9 (75.0) | 1 (8.3) | 11 (91.7) |
 II | 15 | 13 (86.7) | 2 (13.3) | 9 (60.0) | 6 (40.0) | 3 (20.0) | 12 (80.0) | 3 (20.0) | 12 (80.0) |
 III | 12 | 11 (91.7) | 1 (8.3) | 6 (50.0) | 6 (50.0) | 2 (16.7) | 10 (83.3) | 1 (8.3) | 11 (91.7) |
 IV | 31 | 25 (80.6) | 6 (19.4) | 7 (22.6) | 24 (77.4) | 3 (9.7) | 28 (90.3) | 4 (12.9) | 27 (87.1) |
 bp-value |  | 0.42 | 0.002** | 0.60 | 0.77 | ||||
Tumor size (cm | |||||||||
 < 4 | 25 | 21 (84.0) | 4 (16.0) | 14 (56.0) | 11 (44.0) | 2 (8.0) | 23 (92.0) | 4 (16.0) | 21 (84.0) |
 ≥ 4 | 45 | 36 (80.0) | 9 (20.0) | 18 (40.0) | 27 (60.0) | 9 (20.0) | 36 (80.0) | 5 (11.1) | 40 (88.9) |
 ap-value |  | 0.76 | 0.22 | 0.31 | 71.2 | ||||
Laterality | |||||||||
 Left | 36 | 27 (75.0) | 9 (25.0) | 12 (33.3) | 24 (66.7) | 3 (8.3) | 33 (91.7) | 2 (5.6) | 34 (94.4) |
 Right | 34 | 30 (88.2) | 4 (11.8) | 20 (58.8) | 14 (41.2) | 8 (23.5) | 26 (76.5) | 7 (20.6) | 27 (79.4) |
 ap-value |  | 0.22 | 0.04* | 0.10 | 0.08 | ||||
LN metastasis | |||||||||
 No | 34 | 28 (82.4) | 6 (17.6) | 17 (50.0) | 17 (50.0) | 5 (14.7) | 29 (85.3) | 5 (14.7) | 29 (85.3) |
 Yes | 36 | 29 (80.6) | 7 (19.4) | 15 (41.7) | 21 (58.3) | 6 (16.7) | 30 (83.3) | 4 (11.1) | 32 (88.9) |
 ap-value |  | 1.0 | 0.63 | 1.0 | 0.73 | ||||
EGFR mutation | |||||||||
 Wild type | 40 | 32 (80.0) | 8 (20.0) | 19 (47.5) | 21 (52.5) | 8 (20.0) | 32 (80.0) | 6 (15.0) | 34 (85.0) |
 Mutant | 21 | 17 (80.95) | 4 (19.05) | 7 (33.3) | 14 (66.7) | 2 (9.5) | 19 (90.5) | 2 (9.5) | 19 (90.5) |
 Unknown | 9 | 8 (88.9) | 1 (11.1) | 6 (66.7) | 3 (33.3) | 1 (11.1) | 8 (88.9) | 1 (11.1) | 8 (88.9) |
 bp-value |  | 0.82 | 0.23 | 0.52 | 0.82 | ||||